Literature DB >> 23953334

A 50-year journey to cure childhood acute lymphoblastic leukemia.

Ching-Hon Pui1, William E Evans.   

Abstract

The 50th anniversary of Seminars in Hematology coincides with the 50th anniversary of St. Jude Children's Research Hospital, and both milestones are inexorably linked to studies contributing to the cure of childhood acute lymphoblastic leukemia (ALL). We thought it fitting, therefore, to mark these events by traveling back in time to point out some of the achievements, institutions, study groups, and individuals that have made cure of childhood ALL a reality. In many instances, progress was driven by new ideas, while in others it was driven by new experimental tools that allowed more precise assessment of the biology of leukemic blasts and their utility in selecting therapy. We also discuss a number of contemporary advances that point the way to exciting future directions. Whatever pathways are taken, a clear challenge will be to use emerging genome-based or immunologic-based treatment options in ways that will enhance, rather than duplicate or compromise, recent gains in outcome with classic cytotoxic chemotherapy. The theme of this journey serves as a reminder of the chief ingredient of any research directed to a catastrophic disease such as ALL. It is the audacity of a small group of investigators who confronted a childhood cancer with the goal of cure, not palliation, as their mindset.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23953334      PMCID: PMC3771494          DOI: 10.1053/j.seminhematol.2013.06.007

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  104 in total

1.  Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

Authors:  C Liu; J D Kawedia; C Cheng; D Pei; C A Fernandez; X Cai; K R Crews; S C Kaste; J C Panetta; W P Bowman; S Jeha; J T Sandlund; W E Evans; C-H Pui; M V Relling
Journal:  Leukemia       Date:  2012-04-09       Impact factor: 11.528

2.  The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011.

Authors:  Stephen P Hunger; Andre Baruchel; Andrea Biondi; William E Evans; Sima Jeha; Mignon Loh; Anja Moericke; Rob Pieters; Mary V Relling; Kjeld Schmiegelow; Martin Schrappe; Lewis B Silverman; Martin Stanulla; Maria Grazia Valsecchi; Ajay Vora; Ching-Hon Pui
Journal:  Pediatr Blood Cancer       Date:  2012-09-28       Impact factor: 3.167

3.  Reducing delayed intensification therapy in childhood ALL.

Authors:  Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2013-02-08       Impact factor: 41.316

4.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

Authors:  M V Relling; M L Hancock; G K Rivera; J T Sandlund; R C Ribeiro; E Y Krynetski; C H Pui; W E Evans
Journal:  J Natl Cancer Inst       Date:  1999-12-01       Impact factor: 13.506

5.  Genome-wide study of methotrexate clearance replicates SLCO1B1.

Authors:  Laura B Ramsey; John C Panetta; Colton Smith; Wenjian Yang; Yiping Fan; Naomi J Winick; Paul L Martin; Cheng Cheng; Meenakshi Devidas; Ching-Hon Pui; William E Evans; Stephen P Hunger; Mignon Loh; Mary V Relling
Journal:  Blood       Date:  2012-12-11       Impact factor: 22.113

6.  High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

Authors:  Susan O'Brien; Gary Schiller; John Lister; Lloyd Damon; Stuart Goldberg; Walter Aulitzky; Dina Ben-Yehuda; Wendy Stock; Steven Coutre; Dan Douer; Leonard T Heffner; Melissa Larson; Karen Seiter; Scott Smith; Sarit Assouline; Philip Kuriakose; Lori Maness; Arnon Nagler; Jacob Rowe; Markus Schaich; Ofer Shpilberg; Karen Yee; Guenter Schmieder; Jeffrey A Silverman; Deborah Thomas; Steven R Deitcher; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

7.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Malek Faham; Jianbiao Zheng; Martin Moorhead; Victoria E H Carlton; Patricia Stow; Elaine Coustan-Smith; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

8.  The genomic landscape of hypodiploid acute lymphoblastic leukemia.

Authors:  Linda Holmfeldt; Lei Wei; Ernesto Diaz-Flores; Michael Walsh; Jinghui Zhang; Li Ding; Debbie Payne-Turner; Michelle Churchman; Anna Andersson; Shann-Ching Chen; Kelly McCastlain; Jared Becksfort; Jing Ma; Gang Wu; Samir N Patel; Susan L Heatley; Letha A Phillips; Guangchun Song; John Easton; Matthew Parker; Xiang Chen; Michael Rusch; Kristy Boggs; Bhavin Vadodaria; Erin Hedlund; Christina Drenberg; Sharyn Baker; Deqing Pei; Cheng Cheng; Robert Huether; Charles Lu; Robert S Fulton; Lucinda L Fulton; Yashodhan Tabib; David J Dooling; Kerri Ochoa; Mark Minden; Ian D Lewis; L Bik To; Paula Marlton; Andrew W Roberts; Gordana Raca; Wendy Stock; Geoffrey Neale; Hans G Drexler; Ross A Dickins; David W Ellison; Sheila A Shurtleff; Ching-Hon Pui; Raul C Ribeiro; Meenakshi Devidas; Andrew J Carroll; Nyla A Heerema; Brent Wood; Michael J Borowitz; Julie M Gastier-Foster; Susana C Raimondi; Elaine R Mardis; Richard K Wilson; James R Downing; Stephen P Hunger; Mignon L Loh; Charles G Mullighan
Journal:  Nat Genet       Date:  2013-01-20       Impact factor: 38.330

9.  Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

Authors:  Ajay Vora; Nick Goulden; Rachel Wade; Chris Mitchell; Jeremy Hancock; Rachael Hough; Clare Rowntree; Sue Richards
Journal:  Lancet Oncol       Date:  2013-02-07       Impact factor: 41.316

Review 10.  Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia.

Authors:  Sue Richards; Ching-Hon Pui; Paul Gayon
Journal:  Pediatr Blood Cancer       Date:  2012-06-12       Impact factor: 3.167

View more
  98 in total

1.  Treatment Complications and Survival Among Children and Young Adults With Acute Lymphoblastic Leukemia.

Authors:  Elysia M Alvarez; Marcio Malogolowkin; Jeffrey S Hoch; Qian Li; Ann Brunson; Brad H Pollock; Lori Muffly; Ted Wun; Theresa H M Keegan
Journal:  JCO Oncol Pract       Date:  2020-06-11

Review 2.  L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.

Authors:  Gaurav Goyal; Vijaya Raj Bhatt
Journal:  Future Oncol       Date:  2015-08-14       Impact factor: 3.404

3.  Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.

Authors:  Emily R Finch; Colton A Smith; Wenjian Yang; Yiwei Liu; Nancy M Kornegay; John C Panetta; Kristine R Crews; Alejandro R Molinelli; Cheng Cheng; Deqing Pei; Laura B Ramsey; Seth E Karol; Hiroto Inaba; John T Sandlund; Monika Metzger; William E Evans; Sima Jeha; Ching-Hon Pui; Mary V Relling
Journal:  Pediatr Blood Cancer       Date:  2019-10-14       Impact factor: 3.167

4.  Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study.

Authors:  Lisa M Jacola; Kim Edelstein; Wei Liu; Ching-Hon Pui; Robert Hayashi; Nina S Kadan-Lottick; Deokumar Srivastava; Tara Henderson; Wendy Leisenring; Leslie L Robison; Gregory T Armstrong; Kevin R Krull
Journal:  Lancet Psychiatry       Date:  2016-09-14       Impact factor: 27.083

Review 5.  Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia.

Authors:  Emily B Heikamp; Ching-Hon Pui
Journal:  J Pediatr       Date:  2018-09-10       Impact factor: 4.406

Review 6.  Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.

Authors:  Allen E J Yeoh; Daryl Tan; Chi-Kong Li; Hiroki Hori; Eric Tse; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2013-11       Impact factor: 41.316

7.  Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Authors:  Haiying Qin; Monica Cho; Waleed Haso; Ling Zhang; Sarah K Tasian; Htoo Zarni Oo; Gian Luca Negri; Yongshun Lin; Jizhong Zou; Barbara S Mallon; Shannon Maude; David T Teachey; David M Barrett; Rimas J Orentas; Mads Daugaard; Poul H B Sorensen; Stephan A Grupp; Terry J Fry
Journal:  Blood       Date:  2015-06-03       Impact factor: 22.113

Review 8.  Blinatumomab for the treatment of acute lymphoblastic leukemia.

Authors:  Jason B Kaplan; Marina Grischenko; Francis J Giles
Journal:  Invest New Drugs       Date:  2015-09-17       Impact factor: 3.850

9.  Patient-reported outcomes in survivors of childhood hematologic malignancies with hematopoietic stem cell transplant.

Authors:  Hsiu-Ju Yen; Hesham M Eissa; Neel S Bhatt; Sujuan Huang; Matthew J Ehrhardt; Nickhill Bhakta; Kirsten K Ness; Kevin R Krull; D Kumar Srivastava; Leslie L Robison; Melissa M Hudson; I-Chan Huang
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

Review 10.  Obesity and Metabolic Syndrome Among Adult Survivors of Childhood Leukemia.

Authors:  Todd M Gibson; Matthew J Ehrhardt; Kirsten K Ness
Journal:  Curr Treat Options Oncol       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.